Immune function marker does not predict benefit of trastuzumab in HER-2+ breast cancer
12/15/2014
A marker of immune function that predicts for better outcomes in patients treated with chemotherapy for triple negative breast cancer is also linked to improved prognosis in patients treated with...
Hormone-unrelated breast cancer death rate lowered by reducing dietary fat
12/15/2014
Researchers found that death rates in early-stage breast cancer patients with hormone-unrelated breast cancer fell significantly, following a reduction in dietary fat intake.
Genotyping errors plague CYP2D6 testing for tamoxifen therapy
12/15/2014
Clinical recommendations discouraging the use of CYP2D6 gene testing to guide tamoxifen therapy in breast cancer patients are based on studies with flawed methodology and should be reconsidered...
The first long-term study of a pioneering endoscopic laser treatment for early vocal-cord cancer, developed at Massachusetts General Hospital (MGH) and previously shown to provide optimal voice...
Supplemental ultrasound screening for all U.S. women with dense breasts would substantially increase healthcare costs with little improvement in overall health, according to senior author Anna...
The use of hypofractionated whole-breast irradiation (HF-WBI) for patients with early-stage breast cancer increased 17.
Discovery of possible genetic link in pediatric leukemia treatment-related cognitive issues
12/13/2014
Common variations in four genes related to brain inflammation or cells' response to damage from oxidation may contribute to the problems with memory, learning and other cognitive functions seen in...
In patients with BRCA1/2 mutations, common chemotherapy not found to be heart toxic
12/13/2014
Use of anthracycline-based chemotherapy, a common treatment for breast cancer, has negligible cardiac toxicity in women whose tumors have BRCA1/2 mutations -- despite preclinical evidence that such...
At 2014 San Antonio Breast Cancer Symposium three new Myriad studies highlighted
12/13/2014
Myriad Genetics, Inc. (NASDAQ: MYGN) has announced results from a new study that demonstrated the ability of the myRisk™ Hereditary Cancer test to detect 105 percent more mutations in cancer...
FDA approves Gardasil 9 for prevention of certain cancers caused by five additional types of HPV
12/12/2014
The U.S. Food and Drug Administration has approved Gardasil 9 (Human Papillomavirus 9-valent Vaccine, Recombinant) for the prevention of certain diseases caused by nine types of Human...